GT Biopharma (NASDAQ:GTBP) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

GT Biopharma (NASDAQ:GTBP) released its quarterly earnings data on Friday. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.04), FiscalAI reports.

GT Biopharma Price Performance

NASDAQ:GTBP opened at $0.30 on Friday. The firm has a market capitalization of $13.12 million, a P/E ratio of -0.05 and a beta of 0.90. The company’s fifty day moving average price is $0.39 and its 200-day moving average price is $0.42. GT Biopharma has a 1-year low of $0.26 and a 1-year high of $1.53.

Analysts Set New Price Targets

Several brokerages recently issued reports on GTBP. Weiss Ratings reiterated a “sell (e+)” rating on shares of GT Biopharma in a research report on Wednesday, July 8th. Wall Street Zen upgraded shares of GT Biopharma to a “hold” rating in a research report on Saturday, June 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

About GT Biopharma

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).